NZ628969A - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme - Google Patents

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Info

Publication number
NZ628969A
NZ628969A NZ628969A NZ62896913A NZ628969A NZ 628969 A NZ628969 A NZ 628969A NZ 628969 A NZ628969 A NZ 628969A NZ 62896913 A NZ62896913 A NZ 62896913A NZ 628969 A NZ628969 A NZ 628969A
Authority
NZ
New Zealand
Prior art keywords
pyrimidin
pyrazolo
methyl sulfamate
ylamino
dihydroxy
Prior art date
Application number
NZ628969A
Other languages
English (en)
Inventor
Roushan Afroze
Indu T Bharathan
Jeffrey P Ciavarri
Paul E Fleming
Jeffrey L Gaulin
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingchun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ628969A publication Critical patent/NZ628969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ628969A 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme NZ628969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (1)

Publication Number Publication Date
NZ628969A true NZ628969A (en) 2017-03-31

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628969A NZ628969A (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Country Status (30)

Country Link
US (4) US9290500B2 (enExample)
EP (3) EP3173413B1 (enExample)
JP (1) JP6122877B2 (enExample)
KR (1) KR20140123104A (enExample)
CN (1) CN104136399B (enExample)
AR (1) AR092797A1 (enExample)
BR (1) BR112014020365B1 (enExample)
CA (1) CA2864672C (enExample)
CL (1) CL2014002181A1 (enExample)
CO (1) CO7071135A2 (enExample)
CR (1) CR20140380A (enExample)
DO (1) DOP2014000187A (enExample)
EA (1) EA035020B1 (enExample)
EC (1) ECSP14019113A (enExample)
ES (1) ES2739150T3 (enExample)
GE (1) GEP201706687B (enExample)
HK (1) HK1201817A1 (enExample)
IL (1) IL234016A0 (enExample)
MA (1) MA35932B1 (enExample)
MX (1) MX352963B (enExample)
NZ (1) NZ628969A (enExample)
PE (1) PE20142244A1 (enExample)
PH (1) PH12014501832A1 (enExample)
SG (2) SG10201606581RA (enExample)
TN (1) TN2014000351A1 (enExample)
TW (1) TWI593688B (enExample)
UA (1) UA116534C2 (enExample)
UY (1) UY34629A (enExample)
WO (1) WO2013123169A1 (enExample)
ZA (1) ZA201406103B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
BR112015032902A8 (pt) 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
EP3901159A1 (en) * 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TW201628621A (zh) * 2014-10-29 2016-08-16 千禧製藥公司 泛素活化酶抑制劑及輻射之施用
EP3212650B1 (en) 2014-10-29 2021-02-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023901A1 (en) 2002-02-28 2004-02-05 Cook Phillip D. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN1701073B (zh) 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ユビキチンリガーゼ阻害剤
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN106008512B (zh) 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
JP4953472B2 (ja) * 2006-02-28 2012-06-13 ラム・リサーチ・アクチエンゲゼルシヤフト ディスク状物品を液体処理する装置及び方法
HRP20110017T1 (hr) * 2006-08-08 2011-02-28 Millennium Pharmaceuticals Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン,インコーポレーテッド 抗菌剤
KR101925902B1 (ko) * 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 E1 활성화 효소 억제제의 합성 방법
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG10201402148SA (en) * 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MX2014002015A (es) 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
BR112015032902A8 (pt) 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
EP3901159A1 (en) 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Also Published As

Publication number Publication date
US10202389B2 (en) 2019-02-12
ZA201406103B (en) 2017-11-29
US9663525B2 (en) 2017-05-30
JP6122877B2 (ja) 2017-04-26
CO7071135A2 (es) 2014-09-30
MA35932B1 (fr) 2014-12-01
ES2739150T3 (es) 2020-01-29
US20130217682A1 (en) 2013-08-22
EP2814791A1 (en) 2014-12-24
CN104136399A (zh) 2014-11-05
CA2864672A1 (en) 2013-08-22
CR20140380A (es) 2014-10-28
PE20142244A1 (es) 2015-01-07
PH12014501832A1 (en) 2014-11-17
US9290500B2 (en) 2016-03-22
UA116534C2 (uk) 2018-04-10
KR20140123104A (ko) 2014-10-21
HK1201817A1 (en) 2015-09-11
EP3173413B1 (en) 2019-05-01
BR112014020365A2 (pt) 2020-12-22
US20170369499A1 (en) 2017-12-28
TW201345909A (zh) 2013-11-16
GEP201706687B (en) 2017-06-26
DOP2014000187A (es) 2014-10-15
EP3173413A1 (en) 2017-05-31
EA201400831A1 (ru) 2014-12-30
WO2013123169A1 (en) 2013-08-22
SG10201606581RA (en) 2016-09-29
TWI593688B (zh) 2017-08-01
US20160244455A1 (en) 2016-08-25
US20170217968A1 (en) 2017-08-03
MX352963B (es) 2017-12-15
US9796725B2 (en) 2017-10-24
AR092797A1 (es) 2015-05-06
EP2814791A4 (en) 2015-08-19
TN2014000351A1 (en) 2015-12-21
EP3536692B1 (en) 2021-04-07
CL2014002181A1 (es) 2014-12-12
MX2014009944A (es) 2014-11-10
IL234016A0 (en) 2014-09-30
JP2015508775A (ja) 2015-03-23
UY34629A (es) 2013-09-02
US20140088096A9 (en) 2014-03-27
CN104136399B (zh) 2018-08-07
EA035020B1 (ru) 2020-04-17
BR112014020365B1 (pt) 2023-02-23
EP3536692A1 (en) 2019-09-11
CA2864672C (en) 2018-01-09
ECSP14019113A (es) 2015-09-30
SG11201404757WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
MX387207B (es) Inhibidores de proteína quinasa, método de preparación y su uso médico.
PH12012500690A1 (en) Positive allosteric modulators (pam)
JP2014051526A5 (enExample)
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
MX348920B (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
NZ734744A (en) Aryl-or heteroaryl-substituted benzene compounds
PE20110575A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
PH12016500427A1 (en) Ethynyl derivatives
PH12012500867A1 (en) Ethynyl derivatives
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
MX2021014319A (es) Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
PE20211776A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
PH12016501481B1 (en) Ethynyl derivatives
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500261A1 (en) Arylethynyl pyrimidines

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 FEB 2020 BY HENRY HUGHES IP LIMITED

Effective date: 20171009

LAPS Patent lapsed